

IHI Call Days | Call 9

- **CARDIOMET**
Tackling the cardiometabolic “pandemic”

Contact person name: Stephane COMMANS

Organisation: IHU ICAN


E-mail: s.commans@ihuican.org

Challenges and objectives

- What problem(s) are you trying to solve
 - **Rising burden of cardiometabolic diseases**
 - **Plurality of risk factors can now be addressed through novel pharmaceuticals**
 - **Today's care approach remains fragmented and incomplete through siloed clinical practice** and services
- Which IHI specific objective(s) are you addressing?
 - **Topic 2:** integrate fragmented health research and innovation efforts bringing together health industry sectors and other stakeholders, focussing on unmet public health needs, to enable the development of tools, data, platforms, technologies and processes for improved prediction, prevention, interception, diagnosis, treatment and management of diseases, meeting the needs of end-users;
- Which unmet public health need are you addressing?
 - **Coordinated and comprehensive care management promoting cardiometabolic multidisciplinary team** focusing on achievable goals and means

Your approach to solve the problem

- 1) Qualify novel tools for better patient stratification taking into account the multiplicity of cardiometabolic risk factors through the implementation a European data integration hub for future AI-based multi-modality algorithms development, building on lessons learned from previous EU funded projects (MAESTRIA, LITMUS, LIVERAIM and ARTEMIS...as examples)
- 2) Develop multi-disciplinary care pathways for cardiometabolic patients coming from various medical specialties in order to improve their quality of life focusing on autonomy and mobility and out-hospital care management
- 3) Disseminate and train the next generation of european healthcare professionals and patients



Is your project suitable for IHI?


- Public-Private collaboration is essential for the development of these novel diagnostic, prognostic, monitoring and care management tools to ensure that novel pharmacotherapies can be translated into wider clinical practices, ensuring the tailored treatment for each individual cardiometabolic patient

This project will need the contribution of different types of industrial actors:

Pharmaceutical companies providing and developing novel cardiometabolic pharmacotherapies

Biomarkers field for novel diagnostic, prognostic & monitoring tools (from in vitro diagnostics, medical devices & medical imaging fields)

IT & AI companies to ensure the built up of a sustainable European cardiometabolic federated data infrastructure for efficient data sharing & analysis taking advantage of the GAIA-X ecosystem



Outcomes and Impact

- What do you expect out of your proposal in terms of concrete results/outcomes and impact?
 - **Development of novel cardiometabolic patients pathways**
 - **Qualification of novel** diagnostic, prognostic, monitoring and care management **tools** (such as biomarkers or risk scores) focusing on multimodality approaches and AI-powered risk-prediction algorithms
- How do you envisage your proposal to ensure translation from research to innovative solutions that can be integrated/implemented into the healthcare ecosystem
 - **Training the European healthcare professionals and patients on cardiometabolic diseases management**
 - **New nursing protocols or programs to teach paramedics to explore the necessary cross-disciplinary biomarkers**
- How does your project proposal contribute to strengthening the competitiveness of the Union's health industry?
 - Innovative care management of cardiometabolic diseases
- How does your project proposal contribute to the expected benefits for patients?
 - **Ensure faster, complete and equitable translation of novel cardiometabolic pharmacotherapies** into wider clinical practice
 - **Tailored treatment of each cardiometabolic patient** based on the analysis of robust and cost-effective set of biomarkers linking heart and metabolism



Expertise and resources

- We have:
 - A CORE set of willing academic and SMEs partners coming from the various European projects IHU ICAN is / has been involved in (such as MAESTRIA, LITMUS, LIVERAIM or ARTEMIS...)

Pr V RATZIU
Hepatologist
LITMUS / LIVERAIM / ARTEMIS



Pr S HATEM
Cardiologist
MAESTRIA

- We are looking for:
 - Pharmaceutical companies willing to bring in-kind contributions, especially with clinical trials data
 - IT & AI companies who could help with the cardiometabolic federated data infrastructure